Adagio Medical shares surge 11.93% premarket after appointing two senior executives to accelerate commercialization of Ultra-Low Temperature Cardiac Ablation technology.

Adagio Medical (ADGM) rose 11.93% in premarket trading following the announcement of two key executive appointments: Marie-Claude Jacques as Senior Vice President of Global Sales and Antwan Gipson as Senior Vice President of Manufacturing & Operations. The hires, highlighted as pivotal for commercializing the company’s proprietary Ultra-Low Temperature Cardiac Ablation (ULTC) technology, underscored Adagio’s readiness for the 2026 launch of its vCLAS™ Cryoablation System. Jacques, with a track record of scaling disruptive medtech products (e.g., Baylis Medical’s acquisition by Boston Scientific), and Gipson, an operations leader with expertise in scaling manufacturing, were positioned to strengthen global sales execution and cost-efficient production. CEO Todd Usen emphasized their roles in achieving FDA approval for the vCLAS system via the FULCRUM-VT trial and expanding commercial access in the U.S. and Europe. The appointments signaled investor confidence in Adagio’s path to market leadership in cardiac ablation.